global next-generation antibody therapeutics market is expected to grow at 21% cagr during 2015 –...

GLOBAL INDUSTRY INSIGHT: Next-generation Antibody Therapeutics Market Size, Share,

Development, Growth and Demand Forecast to 2020

© P&S Market Research. All rights reserved 2

Global Next-generation Antibody Therapeutics Market Size,

Share, Development, Growth and Demand Forecast to 2020

The global next-generation antibody therapeutics market was valued at $1,490.0 million in 2014

and it is expected to grow at a CAGR of 20.9% during the period 2015 - 2020. The global next-

generation antibody therapeutics market is increasing due to growing global R&D activities. Various

pharmaceutical and biotechnology companies are engaged in R&D for new improved next-

generation antibody therapeutics, which would help in improved treatment of various chronic

diseases, such as cancer, diabetes, cardiovascular diseases, infectious diseases and others. In

addition, various pharmaceutical and biotechnology companies are involved in collaborations with

other companies and organizations for the research and development of next-generation antibody

therapeutics. Technological advancements in the field of next-generation antibody therapeutics are

also driving the market. Recombinant technology has facilitated development of new and improved

antibody therapeutics. Antibodies are genetically engineered to create smaller fragments of

antibodies in order to increase their penetration into cancer cells. Such advancements in

technology have resulted in the improved treatment options; and thus, are gaining popularity.

Based on therapeutic area, the autoimmune/inflammatory next-generation antibody therapeutics

market is expected to witness the faster growth during the forecast period of 2015-2020. On the

basis of technology, the next-generation antibody therapeutics market can be segmented as

antibody-drug conjugates (ADCs), bispecific antibodies, Fc-engineered antibodies, antibody

fragments and antibody-like proteins, and biosimilar antibody products. The biosimilar antibody

products segment is expected to witness the fastest growth, CAGR of 22.5%, during the period

2015 – 2020.

The information and data in the publication “Global Next-generation Antibody Therapeutics

Market Size, Share, Development, Growth and Demand Forecast to 2020” represent the

research and analysis of data from various primary and secondary sources. Bottom-up approach

has been used to calculate the global next-generation antibody therapeutics market by therapeutic

area and technology. The market numbers for countries are obtained through top-down approach.

P&S Market Research analysts and consultants interact with leading companies of the concerned

domain to substantiate every single data presented in this report. We base our primary research on

discussions with prominent professionals and analysts in the industry, aided by informed and

detailed online and offline research.

Biosimilar antibody product refers to a copy of an already-authorized product, whose patent has

expired. The cost of biosimilar antibody products being very low, as compared to the original




antibody products, drives the demand of biosimilar antibody products market, specifically in low

income regions and emerging markets of Asia-Pacific, Latin America, and Eastern Europe.

The increasing healthcare expenditure across the globe is encouraging consumers to use more

number of next-generation antibody therapeutics to get improved treatment. Governments of

various countries have been taking initiatives to provide improved healthcare facilities at affordable

prices. In addition, another factor including growing prevalence of chronic diseases is driving the

next-generation antibody therapeutics market at a significant rate. Next-generation antibody

therapeutics provides improved treatment options for the treatment of chronic diseases, with

minimum side effects.

However, certain restraints such as high cost of next-generation antibody therapeutics and strict

regulatory requirements and long approval time for new drugs are hindering the market growth.

Rural areas in the developing countries are emerging as a potential opportunity for the next-

generation antibody therapeutics market.

The increasing healthcare expenditure and improving healthcare facilities in developing countries,

such as China, India, and Brazil, are laying significant opportunity for next-generation antibody

therapeutics market. North America next-generation antibody therapeutics market is expected to

witness the fastest growth of CAGR 23.5% during the period 2015 – 2020. This is as a result of

increasing number of chronic diseases cases, increasing healthcare expenditure, and rising R&D

investments in the region. In addition, high adoption rate for improved healthcare facilities is

boosting the market for next-generation antibody therapeutics market.

The key companies operating in the global next-generation antibody therapeutics market include

Kyowa Hakko Kirin Co., Ltd., Dyax Corp., AstraZeneca plc, F.Hoffmann-La Roche Ltd, Bayer AG,

Pfizer, Inc., Seattle Genetics, Inc., Bristol-Myers Squibb Company, Takeda Pharmaceuticals

Company Limited, and Biogen.

NEXT-GENERATION ANTIBODY THERAPEUTICS MARKET SEGMENTATION

Next-Generation Antibody Therapeutics Market by Therapeutic Area

• Oncology

• Autoimmune/Inflammatory




Next-Generation Antibody Therapeutics Market by Technology

• Antibody-drug conjugates (ADCs)

• Biosimilar antibody products

• Antibody fragments and antibody-like proteins

• Fc-engineered antibodies

• Bispecific antibodies

GEOGRAPHICAL SEGMENTATION

Next-Generation Antibody Therapeutics Market by Region

• North America

o The U.S.

o Rest of North America

• Europe

o Germany

o The U.K.

o France

o Rest of Europe

• Asia-Pacific

o Japan

o China

o Rest of Asia-Pacific

• Rest of the World (ROW)

TABLE OF CONTENTS




Chapter 1 Research Scope & Methodology

1.1 Market Definition

1.2 Market Scope

1.2.1 Market Breakdown by Therapeutic Area

1.2.2 Market Breakdown by Technology

1.2.3 Market Breakdown by Geography

1.3 Research Methodology and Sources

Chapter 2 Executive Summary

2.1 Key Findings

2.2 Research Summary

2.3 Global Next-Generation Antibody Therapeutics Market Snapshot

Chapter 3 Market Outlook

3.1 Introduction

3.2 Factors Driving the Market and its Impact on Market Forecast

3.2.1 Growing prevalence of chronic diseases

3.2.2 Increasing R&D for improved products

3.2.3 Rising healthcare expenditure

3.2.4 Technological progressions in antibody therapeutics

3.2.5 Impact analysis of drivers on market forecast

3.3 Factors Hindering the Market and its Impact on Market Forecast

3.3.1 Growing threat from unorganized players in Asia-Pacific

3.3.2 Stringent regulatory requirements and time-consuming approval process for new drugs




3.3.3 Impact analysis of restraints on market forecast

3.4 Trends in the Market

3.4.1 Increasing popularity of antibody-drug conjugate (ADC) technology

3.4.2 Rising number of collaborations for R&D of next-generation antibody therapeutics

Chapter 4 Next-Generation Antibody Therapeutics Drug Pipeline Analysis

Chapter 5 Global Market Size and Forecast (2011 – 2020)

5.1 Global Next-Generation Antibody Therapeutics Market Breakdown by Therapeutic Area

5.2 Global Next-Generation Antibody Therapeutics Market Breakdown by Technology

5.3 Global Next-Generation Antibody Therapeutics Market Breakdown by Region

Chapter 6 Next-Generation Antibody Therapeutics Market by Therapeutic Area

6.1 Global Oncology Market

6.1.1 Global oncology market by region

6.2 Global Autoimmune/Inflammatory Market

6.2.1 Global autoimmune/inflammatory market by region

Chapter 7 Next-Generation Antibody Therapeutics Market by Technology

7.1 Global Antibody-Drug Conjugates Market

7.1.1 Global antibody-drug conjugates market by region

7.2 Global Bispecific Antibodies Market

7.2.1 Global bispecific antibodies market by region

7.3 Global Fc-Engineered Antibodies Market

7.3.1 Global Fc-engineered antibodies market by region

7.4 Global Antibody Fragments and Antibody-Like Proteins Market




7.4.1 Global antibody fragments and antibody-like proteins market by region

7.5 Global Biosimilar Antibody Products Market

7.5.1 Global biosimilar antibody products market by region

Chapter 8 Next-Generation Antibody Therapeutics Market by Geography

8.1 North America Next-Generation Antibody Therapeutics Market

8.1.1 North America next-generation antibody therapeutics market breakdown by therapeutic area

8.1.2 North America next-generation antibody therapeutics market breakdown by technology

8.1.3 North America next-generation antibody therapeutics market breakdown by country

8.1.3.1 The U.S. next-generation antibody therapeutics market

8.2 Europe Next-Generation Antibody Therapeutics Market

8.2.1 Europe next-generation antibody therapeutics market breakdown by therapeutic area

8.2.2 Europe next-generation antibody therapeutics market breakdown by technology

8.2.3 Europe next-generation antibody therapeutics market breakdown by country

8.2.3.1 Germany next-generation antibody therapeutics market

8.2.3.2 The U.K. next-generation antibody therapeutics market

8.2.3.3 France next-generation antibody therapeutics market

8.3 Asia Next-Generation Antibody Therapeutics Market

8.3.1 Asia next-generation antibody therapeutics market breakdown by therapeutic area

8.3.2 Asia next-generation antibody therapeutics market breakdown by technology

8.3.3 Asia next-generation antibody therapeutics market breakdown by country

8.3.3.1 Japan next-generation antibody therapeutics market

8.3.3.2 China next-generation antibody therapeutics market




Chapter 9 Competitive Positioning and Market Share Analysis

9.1 Porter's Five Forces of Competitive Position Analysis

9.1.1 Bargaining power of buyers

9.1.2 Bargaining power of suppliers

9.1.3 Threat of new entrants

9.1.4 Intensity of rivalry

9.1.5 Threat of substitutes

9.2 Market Share Analysis

Chapter 10 Company Profiles

10.1 Kyowa Hakko Kirin Co., Ltd.

10.1.1 Business overview

10.1.2 Product and service offerings

10.2 Dyax Corp.



10.3 AstraZeneca plc



10.4 F.Hoffmann-La Roche Ltd



10.5 Bayer AG






10.6 Pfizer, Inc.



10.7 Seattle Genetics, Inc.



10.8 Bristol-Myers Squibb Company



10.9 Takeda Pharmaceuticals Company Limited


10.9.2 Products and services offerings

10.10 Biogen


10.10.2 Products and services offerings

10.11 Strategic Developments in the Next-Generation Antibody Therapeutics Market

Chapter 11 Appendix

11.1 List of Abbreviations

LIST OF TABLES




TABLE 1 SPECIFIC PRIMARY AND SECONDARY SOURCES USED FOR THIS PUBLICATION

TABLE 2 MARKET SNAPSHOT, BY VALUE (2015 AND 2020)

TABLE 3 DRIVERS FOR THE MARKET: IMPACT ANALYSIS

TABLE 4 RESTRAINTS FOR THE MARKET: IMPACT ANALYSIS

TABLE 5 MAJOR MERGERS AND ACQUISITIONS IN THE NEXT-GENERATION ANTIBODY

THERAPEUTICS MARKET (2012 – 2014)

TABLE 6 NEXT-GENERATION ANTIBODY THERAPEUTICS DRUG PIPELINE ANALYSIS

TABLE 7 GLOBAL NEXT-GENERATION ANTIBODY THERAPEUTICS MARKET BREAKDOWN BY

THERAPEUTIC AREA, $M (2011 – 2014)




TECHNOLOGY, $M (2011 – 2014)


TECHNOLOGY, $M (2015 – 2020)


REGION, $M (2011 – 2014)


REGION, $M (2015 – 2020)

TABLE 13 GLOBAL ONCOLOGY MARKET BREAKDOWN BY REGION, $M (2011 – 2014)

TABLE 14 GLOBAL ONCOLOGY MARKET BREAKDOWN BY REGION, $M (2015 – 2020)

TABLE 15 GLOBAL AUTOIMMUNE/INFLAMMATORY MARKET BREAKDOWN BY REGION, $M (2011 –

2014)

TABLE 16 GLOBAL AUTOIMMUNE/INFLAMMATORY MARKET BREAKDOWN BY REGION, $M (2015 –

2020)

TABLE 17 GLOBAL ADCS MARKET BREAKDOWN BY REGION, $M (2011 – 2014)




TABLE 18 GLOBAL ADCS MARKET BREAKDOWN BY REGION, $M (2015 – 2020)

TABLE 19 GLOBAL BSABS MARKET BREAKDOWN BY REGION, $M (2011 – 2014)

TABLE 20 GLOBAL BSABS MARKET BREAKDOWN BY REGION, $M (2015 – 2020)

TABLE 21 GLOBAL FC-ENGINEERED ANTIBODIES MARKET BREAKDOWN BY REGION, $M (2011 –

2014)

TABLE 22 GLOBAL FC-ENGINEERED ANTIBODIES MARKET BREAKDOWN BY REGION, $M (2015 –

2020)

TABLE 23 GLOBAL AF & ALPS MARKET BREAKDOWN BY REGION, $M (2011 – 2014)

TABLE 24 GLOBAL AF & ALPS MARKET BREAKDOWN BY REGION, $M (2015 – 2020)

TABLE 25 GLOBAL BIOSIMILAR AB PRODUCTS MARKET BREAKDOWN BY REGION, $M (2011 – 2014)

TABLE 26 GLOBAL BIOSIMILAR AB PRODUCTS MARKET BREAKDOWN BY REGION, $M (2015 – 2020)

TABLE 27 NORTH AMERICA NEXT-GENERATION ANTIBODY THERAPEUTICS MARKET BREAKDOWN

BY THERAPEUTIC AREA, $M (2011 – 2014)


BY THERAPEUTIC AREA, $M (2015 – 2020)


BY TECHNOLOGY, $M (2011 – 2014)


BY TECHNOLOGY, $M (2015 – 2020)


BY COUNTRY, $M (2011 – 2014)


BY COUNTRY, $M (2015 – 2020)

TABLE 33 EUROPE NEXT-GENERATION ANTIBODY THERAPEUTICS MARKET BREAKDOWN BY








TECHNOLOGY, $M (2011 – 2014)


TECHNOLOGY, $M (2015 – 2020)


COUNTRY, $M (2011 – 2014)


COUNTRY, $M (2015 – 2020)

TABLE 39 ASIA NEXT-GENERATION ANTIBODY THERAPEUTICS MARKET BREAKDOWN BY





TECHNOLOGY, $M (2011 – 2014)


TECHNOLOGY, $M (2015 – 2020)


COUNTRY, $M (2011 – 2014)


COUNTRY, $M (2015 – 2020)

TABLE 45 PRODUCTS AND SERVICES OF KYOWA HAKKO KIRIN CO., LTD.

TABLE 46 PRODUCTS AND SERVICES OF DYAX CORP.

TABLE 47 PRODUCTS AND SERVICES OF ASTRAZENECA PLC

TABLE 48 PRODUCTS AND SERVICES OF F.HOFFMANN-LA ROCHE LTD




TABLE 49 PRODUCTS AND SERVICES OF BAYER AG

TABLE 50 PRODUCTS AND SERVICES OF PFIZER, INC.

TABLE 51 PRODUCTS AND SERVICES OF SEATTLE GENETICS, INC.

TABLE 52 PRODUCTS AND SERVICES OF BRISTOL-MYERS SQUIBB COMPANY

TABLE 53 PRODUCTS AND SERVICES OF TAKEDA PHARMACEUTICALS COMPANY LIMITED

TABLE 54 PRODUCTS AND SERVICES OF BIOGEN

TABLE 55 STRATEGIC DEVELOPMENTS IN THE EMR SYSTEMS MARKET

LIST OF FIGURES

FIG 1 GLOBAL NEXT-GENERATION ANTIBODY THERAPEUTICS MARKET, $M (2011 - 2020)

FIG 2 GLOBAL NEXT-GENERATION ANTIBODY THERAPEUTICS MARKET SHARE, BY TECHNOLOGY

(2014 AND 2020)

FIG 3 GLOBAL NEXT-GENERATION ANTIBODY THERAPEUTICS MARKET SHARE, BY END-USER (2014

AND 2020)

FIG 4 GLOBAL NEXT-GENERATION ANTIBODY THERAPEUTICS MARKET SHARE, BY REGION (2014 AND

2020)

FIG 5 PORTER’S FIVE FORCES OF COMPETITIVE POSITION ANALYSIS

FIG 6 MARKET SHARE ANALYSIS OF KEY COMPETITORS (2014)




About P&S Market Research

P&S Market Research is a global market research and consulting company. We provide market

research reports, industry reports, business intelligence and research based consulting services

across a range of industries.

With the help of our professional corporate relations with various companies, our market research

offers the most accurate market forecasting. Our analysts and consultants interact with leading

companies of the concerned domain to substantiate every single data presented in our publication.

Our research assists our client in identifying new and different windows of opportunity and frame

informed and customized strategies for expansion in different regions.

Contact:

Ms Somya

Manager – Client Partner

347, 5th Ave. #1402

New York City, NY - 10016

Toll-free: +1-888-778-7886 (USA/Canada)

Email: [email protected]

Web: https://www.psmarketresearch.com

mailto:[email protected]

https://www.psmarketresearch.com/

global next-generation antibody therapeutics market is expected to grow at 21% cagr during 2015 –...

Documents